Autopsy report · NCT05785949
Chondro-Gide® Bilayer Collagen Membrane in Knee Cartilage Defect Repair
Cause of deathFunding or business
“The study was terminated early due to a change in business strategy at the sponsor, unrelated to any safety concerns with the medical device.”
Life of this trial
- Ran for about 2 years 11 months before it stopped.
- 75 participants enrolled.
- No results are posted on the registry.
Vital statistics
- Status
- Terminated
- Phase
- Na
- Sponsor
- Geistlich Pharma AG
- Sponsor type
- Industry
- Conditions
- Cartilage Defects
- Interventions
- Microfracture; Chondro-Gide bilayer collagen membrane
- Participants
- 75
- Sites
- 18
- Countries
- China
Trials that died the same way
- Study of Secukinumab in Patients With Newly-diagnosed Type 1 Diabetes Mellitus
“This study was terminated prematurely by the Sponsor for business reasons only.” - A Study of TCD601 (Siplizumab) in New Onset Type 1 Diabetes Patients
“The study has been early terminated due to business reasons. This decision is not related to any safety, efficacy, or regulatory concerns.” - An Evaluation of the Erchonia Laser As a Non-Invasive Treatment to Improve the Appearance of Skin Laxity
“The study was terminated early due to sponsor decision unrelated to safety or efficacy findings” - Study of Ataluren (PTC124) in Hemophilia A and B
“Study was terminated early due to Sponsor decision and not reflective of adverse safety findings.” - A Study of Lorcaserin as Adjunctive Treatment in Participants With Dravet Syndrome
“The study was terminated by Sponsor and the decision was not due to any safety or efficacy reasons.”
Look deeper
- The official registry record (the source of truth)
- Record history: every change the sponsor made
- Open it in the database
Everything here comes from the current ClinicalTrials.gov record. The timeline uses the record’s dates; dates marked planned are the sponsor’s plans. The cause of death is an automatic, unverified label. This is research information, not medical advice.